Documents
Biomedical Catalyst impact evaluation: final report (PDF)
If you cannot open or read this document, you can contact the Web team to request a different format (link will open in a new tab).
Biomedical Catalyst impact evaluation: annexes (PDF)
If you cannot open or read this document, you can contact the Web team to request a different format (link will open in a new tab).
Details
Innovate UK and the Medical Research Council (MRC) commissioned Ipsos Mori to carry out a two-stage review of the Biomedical Catalyst.
This report provides the results of the first stage of the evaluation process.
Some of the report’s main findings include:
- projects receiving Biomedical Catalyst funding progress faster than they would otherwise have done
- Biomedical Catalyst funding encourages companies to switch from low risk or low return projects to those with high risk or higher return
- stakeholders agreed that the Biomedical Catalyst aligns with Innovate UK and MRC strategies
- applicants thought the application process was straightforward and encouraged high-quality submissions
- marketing to the biopharma and academic communities was successful
- the Biomedical Catalyst should seek to increase outreach to the medtech community and emerging sectors such as digital health
Future evaluation of the Biomedical Catalyst
The second phase of the evaluation will begin in 2017 and will build upon this baseline study. It will report on the outcomes and impacts since the launch of the Biomedical Catalyst.
About the Biomedical Catalyst
The Biomedical Catalyst is a partnership between Innovate UK and MRC. It supports the most innovative life sciences opportunities. Its aims are to de-risk innovative science and commercialise the ideas that come from academia and industry. It helps UK SMEs develop into competitive and sustainable businesses.
Updates
- 6 January 2023
Final report document updated to most recent evaluation in 2019.